Stéphane Nancey
YOU?
Author Swipe
View article: IMPACT OF ENDOMETRIOSIS ON THE PROGRESSION OF INFLAMMATORY BOWEL DISEASES: A MULTICENTER RETROSPECTIVE STUDY
IMPACT OF ENDOMETRIOSIS ON THE PROGRESSION OF INFLAMMATORY BOWEL DISEASES: A MULTICENTER RETROSPECTIVE STUDY Open
Introduction: Women with endometriosis have a higher risk of developing inflammatory bowel diseases (IBD). This study aimed to better understanding the impact of endometriosis on the course of IBD. Methods: We conducted a retrospective coh…
View article: Blood proteomic signatures associated with disease activity in inflammatory bowel diseases
Blood proteomic signatures associated with disease activity in inflammatory bowel diseases Open
Background and Aims Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), remain heterogeneous disorders with variable response to biologics. Post-operative recurrence in CD is common despite surgery…
View article: Subcutaneous Infliximab for Perianal Crohn's Disease: The BioLap-Rem Multicenter Study From the GETAID
Subcutaneous Infliximab for Perianal Crohn's Disease: The BioLap-Rem Multicenter Study From the GETAID Open
INTRODUCTION: Intravenous infliximab (IFX) is the cornerstone for treating patients with perianal Crohn's disease (pCD). Data on the recently launched subcutaneous (SC) IFX for pCD are limited. The aim of our study was to evaluate the effe…
View article: Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn’s Disease
Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn’s Disease Open
Background The POWER study (NCT03782376) evaluated efficacy and safety of a single ustekinumab intravenous (IV) reinduction dose versus placebo under continued ustekinumab subcutaneous (SC) treatment in adult patients with moderately to se…
View article: Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis
Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis Open
Tofacitinib and upadacitinib appear to have similar effectiveness and safety profiles when used for the treatment of ASUC.
View article: Advances in Understanding Intestinal Homeostasis: Lessons from Inflammatory Bowel Disease and Monogenic Intestinal Disorder Pathogenesis
Advances in Understanding Intestinal Homeostasis: Lessons from Inflammatory Bowel Disease and Monogenic Intestinal Disorder Pathogenesis Open
Inflammatory bowel diseases (IBDs) are chronic inflammatory conditions of the gastrointestinal tract that are multifactorial in nature. The pathophysiology involves interactions between the host immune system and environmental factors, inc…
View article: Janus Kinase (JAK) Inhibitor-Induced Acne in Inflammatory Bowel Disease: An International, Multicenter, Retrospective Cohort Study
Janus Kinase (JAK) Inhibitor-Induced Acne in Inflammatory Bowel Disease: An International, Multicenter, Retrospective Cohort Study Open
This is the first study characterizing this adverse event in JAK inhibitor-treated patients with IBD and presents the largest cohort of JAK inhibitor-induced acne cases across all immune-mediated diseases. Acne is a common adverse effect r…
View article: The effectiveness of second- and-third-line biologics in perianal Crohn’s disease—a multicenter propensity score-matched study
The effectiveness of second- and-third-line biologics in perianal Crohn’s disease—a multicenter propensity score-matched study Open
Background and Aims Anti-tumor necrosis factor-α inhibitors (anti-TNFs) are the established treatment for perianal Crohn’s disease (pCD), but relapse and non-response are common. Data on second- and third-line biologics are limited. We pre…
View article: Effectiveness and Safety of a Second <scp>JAK</scp> Inhibitor in Ulcerative Colitis: The <scp>J2J</scp> Multicentre Study
Effectiveness and Safety of a Second <span>JAK</span> Inhibitor in Ulcerative Colitis: The <span>J2J</span> Multicentre Study Open
Background While three Janus kinase inhibitors (JAKi) have demonstrated efficacy in ulcerative colitis (UC), scarce data exist regarding JAKi intraclass switching. Aim To evaluate the effectiveness and safety of a second JAK inhibitor in U…
View article: Effectiveness and Safety of Upadacitinib Induction Therapy for 223 Patients With Crohn's Disease: A <scp>GETAID</scp> Multicentre Cohort Study
Effectiveness and Safety of Upadacitinib Induction Therapy for 223 Patients With Crohn's Disease: A <span>GETAID</span> Multicentre Cohort Study Open
Background Real‐world effectiveness and safety of upadacitinib in patients with Crohn's disease (CD) remain unclear. Aims This study aimed to evaluate the effectiveness and safety of upadacitinib in a real‐world cohort. Methods From Septem…
View article: P0684 Real world experience with granulocyte and monocyte adsorptive apheresis (ADACOLUMN®) in patients with refractory inflammatory bowel disease: a retrospective observational multicenter cohort study
P0684 Real world experience with granulocyte and monocyte adsorptive apheresis (ADACOLUMN®) in patients with refractory inflammatory bowel disease: a retrospective observational multicenter cohort study Open
Background Granulocyte and monocyte adsorptive apheresis (GMA) with ADACOLUMN® (JIMRO Takasaki Japan) is an effective and safe therapeutic option for patients with mild to moderate inflammatory bowel disease (IBD) refractory to pharmacolog…
View article: P0872 Corticosteroid sparing effects of treatment with guselkumab in patients with moderately to severely active Crohn’s disease: Phase 3 GRAVITI study results through week 48
P0872 Corticosteroid sparing effects of treatment with guselkumab in patients with moderately to severely active Crohn’s disease: Phase 3 GRAVITI study results through week 48 Open
Background The Phase 3 double-blind, placebo-controlled, treat-through GRAVITI study evaluated the efficacy and safety of subcutaneous (SC) induction and maintenance treatment with guselkumab (GUS), a dual-acting IL-23p19 subunit inhibitor…
View article: P0706 Dose intensification of subcutaneous vedolizumab is an effective and safe option in Inflammatory Bowel Disease patients: Results from the multicentre OPTI-VEDO study
P0706 Dose intensification of subcutaneous vedolizumab is an effective and safe option in Inflammatory Bowel Disease patients: Results from the multicentre OPTI-VEDO study Open
Background Subcutaneous (SC) vedolizumab (VDZ) has demonstrated its efficacy and safety in patients with moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD). This study aimed to evaluate the effectiveness and safety of SC V…
View article: P0654 Switching from intravenous to subcutaneous infliximab: physicians’ practice and patients’ satisfaction - Results from a nationwide transectional study
P0654 Switching from intravenous to subcutaneous infliximab: physicians’ practice and patients’ satisfaction - Results from a nationwide transectional study Open
Background Subcutaneous (SC) infliximab is efficient and safe in inflammatory bowel diseases (IBD), but no guidelines exist regarding practical modalities of switching from IV to SC infliximab. This study aimed to describe current practice…
View article: Impact of Histological Remission for Predicting Clinical Relapse in Crohn’s Disease: A Post Hoc Analysis of the Prospective STORI Cohort
Impact of Histological Remission for Predicting Clinical Relapse in Crohn’s Disease: A Post Hoc Analysis of the Prospective STORI Cohort Open
Background and aims Achieving deep remission, encompassing clinical, endoscopic, and biological remission, is the goal in managing Crohn’s disease (CD). The role of histological remission (HR) remains unclear. This study aimed to examine t…
View article: Real-world effectiveness and safety of CT-P13, an infliximab biosimilar, for inflammatory bowel diseases: A prospective national observational cohort study (ReFLECT study)
Real-world effectiveness and safety of CT-P13, an infliximab biosimilar, for inflammatory bowel diseases: A prospective national observational cohort study (ReFLECT study) Open
ClinicalTrials.gov identifier: NCT02925338.
View article: Post-Discharge Outcomes of Elderly Patients Hospitalized for Inflammatory Bowel Disease Flare Complicated by <i>Clostridioides difficile</i> Infection
Post-Discharge Outcomes of Elderly Patients Hospitalized for Inflammatory Bowel Disease Flare Complicated by <i>Clostridioides difficile</i> Infection Open
Objectives Elderly hospitalized patients with inflammatory bowel disease (IBD) flare and concurrent Clostridioides difficile infection (CDI) are considered at high risk of IBD-related complications. We aimed to evaluate the short-,intermed…
View article: Prevalence of the Oral Corticosteroid Exposure and Excessive Use in Patients with Inflammatory Bowel Disease: Data from Four French Referral Centers of the International DICE Study
Prevalence of the Oral Corticosteroid Exposure and Excessive Use in Patients with Inflammatory Bowel Disease: Data from Four French Referral Centers of the International DICE Study Open
Background: Corticosteroids used to induce a response in Crohn’s disease (CD) and ulcerative colitis (UC) may cause adverse reactions. The DICE study aimed to quantify and investigate factors associated with their use. Methods: This cross-…
View article: Impaired reprogramming of the autophagy flux in maturing dendritic cells from crohn disease patients with core autophagy gene-related polymorphisms
Impaired reprogramming of the autophagy flux in maturing dendritic cells from crohn disease patients with core autophagy gene-related polymorphisms Open
Crohn disease (CD) is an inflammatory bowel disease whose pathogenesis involves inappropriate immune responses toward gut microbiota on genetically predisposed backgrounds. Notably, CD is associated with single-nucleotide polymorphisms aff…
View article: HLA-DQA1*05 Carriage is Associated with treatment failure and the induction of anti-IFX antibodies in IBD patients
HLA-DQA1*05 Carriage is Associated with treatment failure and the induction of anti-IFX antibodies in IBD patients Open
Repeated injections of anti-TNF may induce immunogenicity and loss of response to treatment in IBD (inflammatory bowel disease). An increased risk of immunogenicity in patients with the HLA-DQA1*05 phenotype has been already described. Her…
View article: Peptide‐Based Hydrogel for Nanosystems Encapsulation: the Next Generation of Localized Delivery Systems for the Treatment of Intestinal Inflammations
Peptide‐Based Hydrogel for Nanosystems Encapsulation: the Next Generation of Localized Delivery Systems for the Treatment of Intestinal Inflammations Open
Conventional therapies for inflammatory bowel diseases are mainly based on systemic treatments which cause side effects and toxicity over long‐term administration. Nanoparticles appear as a valid alternative to allow a preferential accumul…
View article: P807 HLA type impact on immunization and efficacy of ustekinumab in IBD patients: a multicenter study
P807 HLA type impact on immunization and efficacy of ustekinumab in IBD patients: a multicenter study Open
Background About 30% of patients treated with ustekinumab will present primary or secondary failure. Outcomes and frequency of ustekinumab immunization are still controversial. Some HLA types (especially DQA1*05) appear to be predictive fa…
View article: P954 Cumulative response to guselkumab through week 24 of induction in patients with moderately to severely active ulcerative colitis: Results from the phase 3 QUASAR induction study
P954 Cumulative response to guselkumab through week 24 of induction in patients with moderately to severely active ulcerative colitis: Results from the phase 3 QUASAR induction study Open
Background The Phase 3 QUASAR induction study evaluated efficacy and safety of guselkumab (GUS), an IL-23p19 subunit antagonist, in pts with moderately to severely active UC. At Week (Wk) 12, GUS 200mg IV was more effective than placebo (P…
View article: P1071 Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID
P1071 Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID Open
Background Several adalimumab preparations are now available on the market for patients with inflammatory bowel disease. Comparative satisfaction and tolerability are unknown. The aim of this study was to investigate inflammatory bowel dis…
View article: DOP23 The role of histology for the prediction of clinical relapse in Crohn’s Disease: A substudy of the STORI cohort
DOP23 The role of histology for the prediction of clinical relapse in Crohn’s Disease: A substudy of the STORI cohort Open
Background Deep remission has become the target in the management of Crohn’s disease (CD). The role of histology in the management of CD has not yet been established. The aim of this work was to study the impact of histological inflammatio…
View article: P857 Effectiveness and safety of subcutaneous infliximab in perianal Crohn's disease: a multicentre cohort study
P857 Effectiveness and safety of subcutaneous infliximab in perianal Crohn's disease: a multicentre cohort study Open
Background Infliximab (IFX) demonstrated its effectiveness in perianal CD (pCD) and represents the first-line medical treatment. A subcutaneous (SC) formulation has recently been developed, however so far it has not been specifically inves…
View article: P884 Patient satisfaction and experience after a switch to an adalimumab biosimilar with high concentration and citrate-free: results from a multicentric prospective real-life study
P884 Patient satisfaction and experience after a switch to an adalimumab biosimilar with high concentration and citrate-free: results from a multicentric prospective real-life study Open
Background Switching from a reference product (RP) to a biosimilar (BS) aims at generating cost savings. Patient adherence after a switch is linked to overall experience that can be impacted by patient or treatment characteristics. This st…
View article: P679 Anti-TNF de-escalation following a treat-to-target strategy with golimumab therapy intensification to reach continuous clinical response in ulcerative colitis: the In-Target GETAID trial
P679 Anti-TNF de-escalation following a treat-to-target strategy with golimumab therapy intensification to reach continuous clinical response in ulcerative colitis: the In-Target GETAID trial Open
Background Achieving deep and continuous remission with tight control could allow de-escalation in patients with UC. The in-TARGET study was a prospective two-phase trial in UC patients initiating golimumab (GLM), that aimed to determine t…